Recent Updates
Recently added Catalysts
TLX Negative Sentiment Score: 25/100

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Telix Pharmaceuticals Limited on behalf of stockholders regarding potential violations of federal securities laws. This comes after Telix received a subpoena from the U.S. Securities and Exchange Commission related to the company's disclosures about its prostate cancer therapeutic candidates. Following this news, Telix's stock experienced a notable decline, with its American Depositary Receipt price dropping by 10.44% on the day after the announcement. The law firm is encouraging investors who experienced losses to reach out for further discussions about their options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix Pharmaceuticals is under investigation for potential violations of federal securities laws.
  • The company's stock price fell significantly following the news of a subpoena from the SEC.
  • The investigation is being driven by losses suffered by Telix stockholders.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) on behalf of Telix stockholders. Our investigation concerns whether Telix has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Telix Pharmaceuticals Limited
Bragar Eagel & Squire

Frequently Asked Questions

How can I contact Bragar Eagel & Squire?

You can reach them at (212) 355-4648 or email investigations@bespc.com.

What prompted the investigation into Telix Pharmaceuticals?

The investigation follows Telix receiving a subpoena from the SEC regarding disclosures.

What happened to Telix's stock price?

Telix's ADR price dropped $1.70, or 10.44%, to close at $14.58 post-subpoena.

What services does Bragar Eagel & Squire provide?

They represent investors in commercial, securities, and complex litigation nationwide.

Is there a cost to consult with Bragar Eagel & Squire?

No, there is no cost or obligation to discuss your claims with them.

Last updated: Aug 23, 2025